Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors

Ítems similars

• Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance
  per: Han, Ruoshuang, et al.
  Publicat: (2021)
• Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
  per: Liu, Xiaozhen, et al.
  Publicat: (2020)
• Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
  per: Liu, Sangtian, et al.
  Publicat: (2021)
• Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
  per: Zhang, Limin, et al.
  Publicat: (2016)
• Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
  per: Jia, Yijun, et al.
  Publicat: (2020)